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Abstract The HMG box domain of the testis determining 
factor, SRY, includes a basic amphiphilic sequence common to 
calmodulin (CAM) binding proteins. By affinity chromatography, 
native gel electrophoresis and fluorescence spectroscopy, we 
show the calcium-dependent binding of SRY to CaM. Binding 
occurs via the HMG box and an SRY peptide of residues 57-80 
binds CaM like the intact domain. SRYICaM complex 
formation is specifically inhibited by the SRY DNA binding site 
sequence, AACAAT, but not a mutated sequence. Fluorescence 
spectra of the SRY/CaM complex indicate 1:1 stoichiometry and 
that binding is accompanied by a conformational change in SRY. 
The A domain of HMG1 also binds CaM and we propose that 
CaM binding is a property of the wider HMG box family, 
including SOX and TCFILEF proteins. These results suggest 
that CaM may regulate the DNA binding activity of HMG box 
transcription factors. 
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1. Introduction 
During mammalian development, expression of the testis 
determining factor, SRY, is necessary and sufficient for the 
development of the indifferent gonad into testes [1]. The DNA 
binding domain of SRY shares homology with a number of 
known or suspected transcription factors of the HMG box 
class [2]. Experiments in vitro suggest hat SRY binds linear 
DNA in a sequence-specific manner [3,4] and causes a bend 
[5,6]. Mutations in the HMG domain of SRY encoded by XY 
gonadal dysgenesis patients affect the DNA binding or DNA 
bending activity of SRY in vitro which is consistent with these 
activities being necessary for testis development [7]. SRY is 
expressed in pre-Sertoli cells of the developing enital ridge, 
but to date, the downstream target genes of SRY or the cel- 
lular factors that mediate its action are not known. 
Calmodulin (CAM) is a major intracellular calcium receptor 
responsible for the inhibition or activation of numerous en- 
zymes. Many nuclear functions are under CaM control and 
some transcriptional activators are known to be modulated 
indirectly through CaM-dependent kinases [8,9]. CaM has 
more recently been shown to influence transcription by inter- 
acting directly with basic helix-loop-helix (bHLH) DNA bind- 
ing proteins through differential inhibition of the DNA bind- 
ing activity of these domains [10]. Given the ubiquitous 
expression of CaM and its binding partner promiscuity, the 
possibility exists that CaM interacts with other transcription 
factors to modulate gene expression. 
A basic amphiphilic ~-helix is a structural feature common 
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to many calmodulin-binding peptides and proteins [11]. The 3- 
D structure of the HMG box of SRY and HMG1 consists of 
three a-helices stabilised by a hydrophobic ore of aromatic 
amino acids [1~14]. In the HMG box of SRY, we observe 
strongly basic sequences in helix 1 and 3 whose core resembles 
the CaM binding region of CaM-dependent protein kinase II, 
RRKLK [11]. On the basis of this similarity, we tested 
whether SRY could interact directly with CaM. 
2. Materials and methods 
2.1. Materials 
The following were obtained from commercial sources: calmodulin 
agarose and protein kinase II peptide 290-309 (LKKFNARRKLK- 
GAILTTMLA) were obtained from Sigma, St. Louis, MO; hog brain 
calmodulin from Boehringer Mannheim. SRY peptides panning the 
HMG domain were synthesised by Nichola O'Reilly, ICRF labora- 
tories, London. 
2.2. Recombinant protein production 
SRY was synthesised in E. cord BL21 (DE3) cells harbouring plas- 
mid pT7-FHK-SRY, which contains the tag sequence MDYKDD- 
DDKHHHHHHRRASV at the N terminus of human SRY. This 
tag specifies a phosphorylation site for heart muscle kinase (under- 
lined). Cells were grown, induced, harvested, sonicated and nucleic 
acids removed as previously described in the Qiagen manual. 1 gg 
SRY (about 80% pure) was phosphorylated by heart muscle kinase 
and [?-a2P]ATP as described previously [15]. 
The HMG box of SRY (residues 55-143) was synthesised in E. coli 
BL21 (DE3) cells harbouring plasmid pT7-hSRYbox88 and purified 
to homogeneity by FPLC as described elsewhere (Borden et al., in 
preparation). The A domain of rat HMG1 was synthesised in E. coli 
BL21 (DE3) cells harbouring plasmid pT7-7 HMGla (a gift from 
M.E. Bianchi) and purified as described [6]. Protein concentrations 
were measured by UV absorption spectroscopy at 280 nm assuming 
absorption coefficients of 21.2 and 8.9 mM -1 cm -a for SRY and 
HMG1 respectively. 
2.3. Calmodulin affinity chromatography 
32P-labelled SRY (5x 106 cpm, 1 gg) in 1 ml 50 mM HEPES pH 
7.9, 100 mM NaC1, 1% bovine serum albumin (buffer A) containing 
1 mM CaC12 was applied to a 0.3 ml calmodulin agarose column 
equilibrated in buffer M1 mM CaC12 and 0.5 ml fractions were col- 
lected. The column was first washed with 5 ml buffer A/1 mM CaC12 
then with 5 ml buffer A/5 mM EDTA. The column was additionally 
washed with 1.5 ml buffer A/0.1% NP40 and 1.5 ml buffer A/l% SDS 
to elute residual protein. Radioactivity in fractions was determined by 
Cerenkov counting and fractions with high counts were analysed by 
SDS-PAGE. 200 gl was removed and precipitated with an equal vo- 
lume ice-cold 20% TCA and the precipitate collected by centrifugation 
and resuspended in SDS-PAGE sample buffer. Proteins were sepa- 
rated on a 12.5% Phast SDS-PAGE gel (Pharmacia) and the air-dried 
gel was autoradiographed. 
2.4. Native polyacrylamide gel electrophoresis (PAGE) 
Gel and buffer composition conditions were essentially as for SDS- 
PAGE in standard Tris-glycine buffers [16] but lacking SDS, and 
consisted of a 12.5% separating el and a 5% stacking gel. Compo- 
nents were added together (10 or 16 ~tl final volume of 20 mM Tris 
pH 6.8, 10% glycerol, 1 mM DTT, 0.1% bromophenol blue) and 
incubated at 4°C for 1 h prior to electrophoresis at 4°C on a BioRad 
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minigel system at 20 mA constant current. Typically 2-6 I.tg CaM, 14 
~tg HMG box or 5 lag peptide were used. In competition experiments, 
various amount of DNA (0.25 1 p.M) were used. DNA oligonucleo- 
tide encoding the consensus SRY binding site, 5'-GTTAACGTAA- 
CAATGAATCTGGTAGA [17], was annealed to its complement. As 
a negative control, the oligonucleotide 5'-GTTAACGTCCGCGG- 
TAATCTGGTAGA, which SRY does not bind, was used. 
2.5. Measurement of fluorescence spectra 
Fluorescence spectra were recorded at 20~C on a Spex Fluoromax 
Fluorimeter using 1 ml cells. The buffer was 25 mM Tris pH 7.0, 0.1 
M KC1, with added 1 mM CaCI2. For titrations with CaM, an ex- 
citation wavelength of 295 nm was used. At this wavelength, the 
emission maximum of CaM, which contains no tryptophan residues, 
is about 308 nm, whereas that of SRY HMG domain (3 Trp residues) 
is at 347 nm and HMG1 A domain (1 Trp residue) is at 337 nm. 
Hence, adding CaM to SRY under these conditions adds negligible 
fluorescence at 350 nm. DNA used was 12mer oligonucleotide with 
the sequence GATAACAATGGC, bearing the high affinity SRY 
DNA binding site, TAACAAT [17]. 
3. Results 
32p-labelled SRY was loaded onto a CaM-agarose column 
in the presence of CaC12 and the column was washed first with 
CaC12 buffer, then with EDTA and collected fractions were 
analysed by SDS-PAGE/autoradiography. SRY migrates at 
27 kDa by SDS-PAGE and Fig. 1 shows that SRY bound 
to the CaM column in the presence of Ca 2+ (fractions 1-5) 
and was eluted by EDTA (fractions 5--8). This suggests that 
SRY interacts with CaM-agarose and that binding is calcium 
dependent. 
To determine if CaM binding occurs in free solution and 
via the HMG box of SRY, purified SRY HMG box was 
electrophoresed in the presence or absence of CaM, and the 
Ca 2+ dependence of this interaction was assessed (Fig. 2a). 
Stained protein bands were not observed in lanes containing 
SRY alone (lanes 1, 4), because SRY migrated toward the 
cathode. In the presence of CaC12, CaM migration is retarded 
(lane 5) relative to that in the presence of EGTA (lane 2). For 
mixtures of SRY and CaM in the presence of EGTA, only 
CaM was observed (lane 3), whereas in the presence of CaC12, 
the migration of CaM was further retarded ue to the forma- 
tion of a Ca2+-CaM-SRY complex (lane 6). The specificity of 
interaction between CaM and SRY was analysed using a 
CaM binding peptide of CaM protein kinase II in a competi- 
tion assay. At equimolar concentrations of PKII peptide and 
SRY, the SRY-CaM complex was dramatically reduced (lane 
7). Given the Kd of PKII peptide-CaM is reportedly 1nM [18] 
we estimate the relative Kd of SRY-CaM interaction is greater 
than 10 nM. 
To further localise the CaM binding region of SRY, eight 
peptides panning the HMG domain were investigated (Fig. 
2b). In the absence of CaM, peptides were not detected in the 
gel (result not shown). In the presence of CaM, peptides from 
two regions of the SRY HMG domain showed an interaction: 
residues 57-80 (lane 1) and a second, weakly binding region, 
131-144, which gave multiple bands (lane 9). No CaM bind- 
ing was detectable with the other six SRY peptides (lanes 3- 
8). Binding affinity of SRY peptides 57-80 (QDRVKRPM- 
NAFIVWSRDQRRKMAL) to CaM was similar to that for 
the whole HMG box; binding of SRY peptides 131-144 
(PRRKAKMLPKNCSL) was about five-fold weaker. Two 
SRY mutations, R62G and R133W, encoded by XY gonadal 
dysgenesis patients, fall in the conserved RRK regions of the 
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Fig. 1. Ca2+-dependent affinity chromatography of SRY on calmo- 
dulin agarose column. SDS-PAGE/autoradiography of eluted col- 
umn fractions. Lanes 14, SRY eluted with buffer A/CaC12; lanes 
5 8, SRY eluted with buffer A/EDTA; lanes 9 and 10, SRY eluted 
with buffer A/0.1% NP40; lanes 11 and 12, SRY eluted with buffer 
All% SDS. On the right side of the gel are the molecular mass 
standards in kDa. FHK-SRY migrates at its predicted molecular 
weight of 27 kDa. 
CaM binding SRY peptides, 57-80 and 131-144 respectively 
[19]. Fig. 2b, lanes 2 and 10, shows that in each case the 
mutant peptide bound CaM. Mobility shift differences can 
be explained by the effect of the mutation upon the charge 
of the peptide. CaM binding is therefore unlikely to be the 
basis for defective SRY function in these patients. 
The effect of DNA upon the CaM binding activity of SRY 
was tested. Mixtures of SRY and 1 ~tM high affinity SRY 
DNA binding site (probe B), whose core is TAACAAT, 
formed DNA/SRY complexes (Fig. 2c, lane 1) whereas non- 
binding site DNA (probe N), with the core GGCGCCT, 
failed to (lane 2). Mixtures of SRY and CaM in the presence 
of CaC12 produced CaM/SRY complex (lane 3) but co-incu- 
bation with increasing probe B DNA (0.25, 0.5, 1.0 ~tM) re- 
suits in reduced CaM/SRY complex formation (lanes 4, 5, 6). 
This loss of CaM/SRY complex is associated with the conco- 
mitant appearance of free CaM and of DNA/SRY complex. 
At 1 ~tM, probe B completely abolishes CaM/SRY complex 
formation (lane 6). This abolition is sequence-dependent as 
1 ~tM probe N has no effect on CaM/SRY complex formation 
(lane 7); inhibition is detected at 10 ktM (not shown). These 
results demonstrate that the affinity of SRY for its DNA 
binding site is significantly larger than for CaM. We conclude 
that specific DNA binding by SRY inhibits its CaM binding 
activity. 
A second HMG box, the A domain of HMG1, was purified 
and tested for CaM binding. Binding affinity was comparable 
with SRY (Fig. 2d, lane 1). The HMG1 mutant, W49R, has 
much of its protein structure destroyed, with < 10% residual 
ct [20]. This protein was stably expressed and bound CaM 
with activity comparable to wild type HMG1 A domain 
(Fig. 2d, lane 2). 
We used the fluorescence properties of SRY and HMG1 to 
further investigate the CaM-HMG box interaction. Addition 
of CaM to 2 ~tM HMG1 increased the fluorescence of the 
HMGla  domain four-fold and saturation was reached at 
equimolar CaM indicating 1:1 stoichiometry. Emission max- 
imum was shifted from 337 nm in free HMG1 to 332 nm in 
the complex (result not shown). We also observed 1: 1 binding 
stoichiometry for the SRY/CaM complex at 1 ~tM and 0.2 
p.M, where signal strength becomes weak (result not shown). 
Addition of CaM greatly increases the fluorescence of SRY 
HMG box, and causes the emission maximum to shift from 
347 nm in the free protein (Fig. 3b, curve 1) to 338 nm in the 
complex (Fig. 3b, curve 2). This shift was calcium-dependent 
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Fig. 2. Non-denaturing polyacrylamide g l electrophoresis of the HMG box of SRY and HMG1 with CaM. The anode is at the bottom of the 
gel. Proteins were visualised by staining with Coomassie brilliant blue. (a) Ca2+-dependent complex formation of SRY HMG box with calmo- 
dulin. Where indicated, 35 [.tM CaM, 40 ktM SRY HMG box and 40 ktM PKII peptide were used in the presence of 5 mM EGTA or 5 mM 
CaC12. Arrows (bottom to top) indicate the position of apoCaM, Ca2+-CaM, Ca2+-CaM/protein kinase II peptide complex and CaM/SRY 
HMG box complex. (b) Peptides from two regions of SRY HMG box bind CaM. 37 FtM CaM and 100 ~tM SRY HMG box peptides were 
mixed in the presence of CaC12. Peptides pan SRY amino acid residues indicated. 57-80m refers to a mutated form of peptide 57-80 with the 
R62G substitution while 131-144m refers to the peptide 131-144 with the R133W substitution. (c) Effect of DNA upon CaM/SRY complex 
formation. DNA was mixed with 17 ktM CaM and 20 I.tM SRY HMG box in the presence of CaCI2. DNA specifying the SRY binding site 'B' 
or a non-binding site sequence 'N' was present at 1 ~tM in lanes 1, 2, 6, 7 and 8 and 'B' is present at 0.25 ktM in lane 4 and 0.5 laM in lane 5. 
Arrows (bottom to top) indicate the position of CaM, CaM/SRY and DNA/SRY. (d) Interaction of 10 ~tM wild type HMG1 A domain or 
W49R mutant HMG1 A domain with 17 ~tM CaM in the presence of 5 mM CaC12. 
because (i) addition of excess EGTA reversed the effect and 
(ii) adding apoCaM to either SRY or HMG1 HMG box 
caused a negligible increase in fluorescence intensity where- 
upon addition of Ca 2+ caused an increase in fluorescence 
(result not shown). Upon adding DNA bearing the SRY bind- 
ing site, AACAAT, the fluorescence of the preformed SRY/ 
CaM complex is quenched (Fig. 3b, curve 3). This decrease to 
less than that for free SRY, with a slight blue shift, indicates 
the preferential formation of an SRY/DNA complex. The 
SRY/DNA complex is shown to have an emission maximum 
only slightly blue-shifted compared with free SRY, but is 
quenched about 50% at saturation (Borden et al., in prepara- 
tion). Taken together with the electrophoretic data, we con- 
clude that DNA and CaM compete for SRY such that only 
binary complexes are formed. 
These results allow us to place some limits on the affinity of 
SRY for CaM. Stoichiometric binding to CaM was obtained 
at 200 nM SRY and given that DNA containing AACAAT 
(Kd -- 15 nM) competes out equimolar CaM, the Kd for CaM 
must be in the 15-200 nM range. This is consistent with the 
electrophoretic data, where SRY binding site DNA competes 
out CaM but non-binding site DNA (Kd of 300 nM [6]) fails 
to compete. 
4. Discussion 
These findings illustrate that the HMG domain of SRY can 
bind CaM with 1 : 1 stoichiometry and in a calcium-dependent 
manner. Binding is competed by PKI I  peptide which suggests 
that SRY, like PKI I  peptide, binds to CaM in a conventional 
way, with the two globular domains of CaM engulfing the tx- 
helix of the target [21]. The moderate affinity we observe 
(Kd < 200 nM) is significantly weaker than the highest affinity 
CaM-dependent enzymes (Kd = 1 nM) but closer to MyoD 
(Kd = 20 nM) and remains potentially relevant at the physio- 
logical level given that CaM concentrations in mammalian 
tissues vary between 2 FtM and 30 ~tM [22]. The HMG1 A 
domain, which bears only 25% sequence identity to SRY [23], 
also binds CaM suggesting that CaM binding is likely to be a 
feature of the wider HMG1 box superfamily, including SOX 
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Fig. 3. Fluorescence measurements of the interaction of HMG box 
of HMG1 or SRY with CaM. (a) Titration of 2 I~M HMG1 with 
increasing CaM concentrations Fo is the fluorescence of HMG1 
alone at 330 nm and F is the observed fluorescence upon CaM ad- 
dition. (b) Fluorescence of 1 ~M SRY (curve 1) or combined with 
1.25 I.tM CaM (curve 2) or SRY-CaM complex as in curve 2 follow- 
ing addition of 0.8 ~tM DNA (lower spectrum). Asterisk denotes 
Raman peak from water. 
[19] and TCF/LEF1 [24] proteins. Although primary sequence 
may not be strongly conserved amongst HMG domain pro- 
teins, basic amphiphilic helix is retained. 
CaM binding is likely to involve SRY amino acids 57 80, 
comprising N-terminal extended chain (residues 57-64) and 
helical region (helix 1 is residues 65-81). These regions make 
extensive contacts with DNA, namely residues R59, R62, 
M64, N65, F67 and 168, R72 and R75 [12]. Presumably 
CaM shares at least part of its SRY binding site with 
DNA, given the competition we observe between these mole- 
cules. 
The effect of CaM and DNA on the fluorescence of HMG 
proteins is dramatically different, with DNA quenching the 
fluorescence, and CaM greatly enhancing it. The possibility 
of F6rster energy transfer from the SRY fluorescence to 
DNA is negligible, indicating that there is some change in 
the environment around the tryptophan residue(s) on forming 
the specific DNA complex. The only tryptophan present in 
HMG1 A domain is W49 (W97 in SRY), which lies near 
the end of the second helix and is completely conserved 
among HMG box proteins. This residue stacks on another 
conserved aromatic residue (F23 in HMG1 and W70 in 
SRY) and forms part of a hydrophobic luster in the 'hinge' 
region of the molecule. Changes in the stacking of this tryp- 
tophan with its neighbour due to changes in the hinge angle 
upon complex formation would readily account for changes in 
the fluorescence emission of this residue, with no requirement 
for a direct contact with either DNA or CaM. The simplest 
explanation for our results is a conformational change in the 
HMG protein upon forming these complexes. The HMG1 A 
domain mutant, W49R, is largely unfolded yet it retains its 
CaM binding activity suggesting that CaM binding is a prop- 
erty of primary and possibly secondary, but not tertiary struc- 
ture elements of the HMG box. So while CaM affects the 
tertiary structure of the HMG box, it is not dependent 
upon it for binding. 
CaM transcription factor interactions involving bHLH pro- 
teins have been demonstrated in vivo, and shown to inhibit 
DNA binding [10,25]. The results described in this paper dem- 
onstrate similar properties for a different class of nuclear pro- 
teins, albeit with lower affinities. The propensity for CaM to 
bind helical basic peptides is well-known, and affinity for 
HMG proteins remains to be demonstrated in vivo. HMG1, 
which is abundant in the nucleus, could translocate CaM to 
other CaM binding transcription factors, e.g. SOX or bHLH 
proteins, in order to regulate their function in concert with 
calcium or cell cycle. 
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